Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label triple therapy with dolutegravir plus 2 NRTIs in treatment-naive HIV-2 infection
2016-000346-61Phase 2Completed
- Sponsor
- Blueclinical
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dolutegravir, abacavir, lamivudine, tenofovir and emtricitabine in human immunodeficiency virus type 2 infection (HIV-2), sponsored by Blueclinical. Primary endpoint: Virologic and immunologic efficacy at Week 48. Started Dec 2016; status: completed.
02
Drugs
dolutegravirabacavirlamivudinetenofoviremtricitabine
03
Conditions
human immunodeficiency virus type 2 infection (HIV-2)
Beyond the preview
Go deeper on 2016-000346-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000346-61.